--- title: "Weekly Recap | Valion Bio -45.33%, weekly low at $1.11" type: "News" locale: "en" url: "https://longbridge.com/en/news/302176138.md" description: "Valion Bio (VBIO) closed the week at $1.17, down 45.33% over the five sessions. The S&P 500 lost 1.95% in the same period, leaving the stock about 43.38 percentage points behind the benchmark. The tape was volatile: Monday opened at $2.10 and printed a weekly high of $2.14 before fading fast, with Tuesday and Wednesday sliding further. Thursday saw a spike in volume to 13.7 million shares and a weekly low of $1.11, before a mild Friday recovery to $1.17. Weekly amplitude reached 49." datetime: "2026-10-17T08:24:26.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/302176138.md) - [en](https://longbridge.com/en/news/302176138.md) - [zh-HK](https://longbridge.com/zh-HK/news/302176138.md) generator: "portal-rs" --- # Weekly Recap | Valion Bio -45.33%, weekly low at $1.11 ## The Week Valion Bio (VBIO) closed the week at $1.17, down 45.33% over the five sessions. The S&P 500 lost 1.95% in the same period, leaving the stock about 43.38 percentage points behind the benchmark. The tape was volatile: Monday opened at $2.10 and printed a weekly high of $2.14 before fading fast, with Tuesday and Wednesday sliding further. Thursday saw a spike in volume to 13.7 million shares and a weekly low of $1.11, before a mild Friday recovery to $1.17. Weekly amplitude reached 49.05%, unusually broad for a micro-cap name. ## Key Events The company’s main story this week was the early feasibility result for LarmorBio BioScan-NMR. Thursday’s release said the initial study supports NMR’s potential to track microbial growth and backs continued development. At the same time, Valion Bio kept facing registration-related pressure: a Saturday S-3 filing proposed the sale of 3.95 million common shares for holders, following a DEF 14A and a DRS filing during the week. Wider biotech reporting on Section 232 tariffs and domestic CDMO demand placed Velocity Bioworks, a Valion Bio unit, in the industry narrative, but the company’s own disclosures centred on NMR progress and the share-sale arrangement. ## Analyst Ratings Only one institution covers the name, and that analyst has no clear opinion; buy, overweight, hold, underweight and sell each stand at zero. The consensus rating and consensus target are not meaningful figures, with the target implying a -100% gap versus the latest price. The stock ranks 460th out of 509 names in the biotech industry group, the lower end of the peer set. Coverage is extremely thin, and there is not enough differentiated view to describe any directional consensus. ## The Week Ahead Next week’s macro calendar tilts toward housing and crude. Monday brings the NAHB housing market index (prior 32, forecast 32), Tuesday has annualised housing starts (prior 1.275, forecast 1.305) and building permits (prior 1.403, forecast 1.395), and Wednesday shows EIA weekly crude and Cushing inventories. Valion Bio has no earnings or company event on the calendar, so near-term attention may stay on the supply pressure implied by the S-3 holders’ sale file, plus any follow-up development news after the NMR feasibility readout. ## In Short This week paired violent price action with very thin institutional coverage. The stock fell more than 45% on heavy mid-week turnover, while the latest session’s capital flow showed small-lot net buying and no large-lot activity, a muddled directional picture. Valuation metrics reflect a tail-end profile: price-to-book is about 0.35x and total market value around $1.5 million. The tension to watch is between the overhang from share sales and whether the NMR technology delivers a clearer clinical or commercial signal. *This article is generated by LongbridgeAI from market data, for information only and not investment advice.* ### Related Stocks - [VBIO.US](https://longbridge.com/en/quote/VBIO.US.md) ## Related News & Research - [Valion Bio Reports Early Results Showing NMR Potential to Track Microbial Growth](https://longbridge.com/en/news/301974094.md) - [Valion Bio files to sell 3.95M shares of common stock for holders](https://longbridge.com/en/news/302158746.md) - [Valion Bio completes initial feasibility evaluation of LarmorBio BioScan-NMR, supports continued development](https://longbridge.com/en/news/301974669.md) - [With Section 232 Tariffs Reshaping Biotech, Valion Bio's Velocity Bioworks Capitalizes on Domestic CDMO Surge | VBIO Stock News](https://longbridge.com/en/news/301842689.md) - [VALION BIO BRIEFS SENIOR DEPARTMENT OF WAR AND BARDA OFFICIALS IN JOINT ENGAGEMENT ON ENTOLIMOD FOR ACUTE RADIATION SYNDROME | VBIO Stock News](https://longbridge.com/en/news/286964504.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**